For example, human APOE4 carriers with FTD, a primary tauopathy, are younger in age at the onset of tau pathology, exhibit signs of exacerbated neurodegeneration, and show greater cognitive decline than non-APOE4 carriers [108, 110]. This evidence concerns the gene MAPT and frontotemporal dementia.